Olutasidenib (Synonyms: FT-2102)
目录号: PL02184 纯度: ≥99%
CAS No. :1887014-12-1
商品编号 规格 价格 会员价 是否有货 数量
PL02184-5mg 5mg ¥4182.50 请登录
PL02184-10mg 10mg ¥6335.00 请登录
PL02184-25mg 25mg ¥8517.00 请登录
PL02184-50mg 50mg ¥12175.00 请登录
PL02184-100mg 100mg ¥16252.00 请登录
PL02184-10mM*1mLinDMSO 10mM*1mLinDMSO ¥4420.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Olutasidenib
中文别名
Olutasidenib; FT-2102; FT 2102; FT210
英文名称
Olutasidenib
英文别名
5-[[(1S)-1-(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile;5-[1-(6-Chloro-2-oxo-1H-quinolin-3-yl)ethylamino]-1-methyl-6-oxopyridine-2-carbonitrile;Olutasidenib
Cas No.
1887014-12-1
分子式
C18H15ClN4O2
分子量
354.79
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Olutasidenib (FT-2102) 是一种,具有口服活性的、能透过血脑屏障的、突变型异柠檬酸脱氢酶 (IDH)1 的选择性有效抑制剂,对IDH1- R132H 和 IDH1- R132C的 IC50 值分别为 21.2 nM 和 114 nM。可用于研究急性髓性白血病或骨髓增生异常综合征。
生物活性
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC 50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
性状
Solid
IC50 & Target[1][2]
IC50: 21.2 nM (IDH1- R132H), 114 nM (IDH1- R132C).
体外研究(In Vitro)
Olutasidenib (FT-2102) potently inhibits 2-HG production by multiple IDH1-R132 mutants (R132H, R132C, R132G, R132L), suggesting Olutasidenib (FT-2102) could be efficacious against most IDH1-R132 mutant-expressing tumors. Olutasidenib (FT-2102) is highly selective for IDH1 isoforms, showing no appreciable inhibition against wild-type IDH1 (> 20 μM) and IDH2 mutants (R172K and R140Q: both > 20 μM). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Olutasidenib (FT-2102, three oral doses (12.5, 25, and 50 mg/kg) in 12-hour intervals) exhibits potent anti-tumor activity in HCT116-IDH1-R132H/+ xenograft bearing female BALB/c Nude mice. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. JM Watts, et al. A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
[2]. Justin A. Caravella, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020.
溶解度数据
In Vitro: DMSO : 125 mg/mL (352.32 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2